Phase I dose escalation of doxorubicin chemotherapy in tumor-bearing equidae

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Background: There is no information on the use of doxorubicin in horses with tumors. Objective: To determine dose-limiting toxicosis (DLT) and maximum tolerated dose (MTD) of doxorubicin in tumor-bearing horses. Animals: Seventeen horses with 34 localized or multicentric advanced tumors. Methods: Two-stage dose-ranging design involving intrapatient and interpatient dose escalation. Treatment protocol included 6 treatment cycles given at 3-week intervals with dosages ranging from 40 to 85 mg/m2. Clinical signs, hematologic, and nonhematologic changes were evaluated. Results: Total doses ranged from 1,127 to 2,900 mg in 12 horses that completed the assigned treatment protocols. The MTD was 75 mg/m2. Hypersensitivity reactions and neutropenia were dose limiting. Hypersensitivity was dose-dependent but schedule invariant. Neutropenia was dose- and cycle-dependent but dose-escalation schedule invariant. Cardiotoxicity was not observed. Conclusion and Clinical Relevance: The recommended dosage of doxorubicin to treat horses is 70 mg/m2 given at 3-week intervals as single agent. Adjunctive treatment with antihistamines and nonsteroidal anti-inflammatory drugs is recommended to control hypersensitivity.

Original languageEnglish (US)
Pages (from-to)1209-1217
Number of pages9
JournalJournal of Veterinary Internal Medicine
Issue number5
StatePublished - Sep 2013


  • Chemotherapy
  • Equine
  • Oncology
  • Oncology treatment

ASJC Scopus subject areas

  • veterinary(all)


Dive into the research topics of 'Phase I dose escalation of doxorubicin chemotherapy in tumor-bearing equidae'. Together they form a unique fingerprint.

Cite this